JP Morgan Chase’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $97M | Sell |
367,781
-171,653
| -32% | -$40.1M | 0.01% | 1091 |
|
|
2026
Q1 | $118M | Buy |
539,434
+32,194
| +6% | +$7.22M | 0.01% | 912 |
|
|
2025
Q4 | $108M | Buy |
507,240
+214,844
| +73% | +$44.4M | 0.01% | 909 |
|
|
2025
Q3 | $58.1M | Buy |
292,396
+84,255
| +40% | +$15.7M | ﹤0.01% | 1319 |
|
|
2025
Q2 | $35.9M | Buy |
208,141
+23,019
| +12% | +$3.75M | ﹤0.01% | 1537 |
|
|
2025
Q1 | $28.9M | Buy |
185,122
+107,695
| +139% | +$15.4M | ﹤0.01% | 1642 |
|
|
2024
Q4 | $10.7M | Buy |
77,427
+37,593
| +94% | +$4.94M | ﹤0.01% | 2631 |
|
|
2024
Q3 | $5.95M | Sell |
39,834
-25,428
| -39% | -$3.43M | ﹤0.01% | 3090 |
|
|
2024
Q2 | $8.9M | Buy |
65,262
+37,256
| +133% | +$5.07M | ﹤0.01% | 2555 |
|
|
2024
Q1 | $4.23M | Sell |
28,006
-33,858
| -55% | -$4.83M | ﹤0.01% | 3233 |
|
|
2023
Q4 | $7.79M | Sell |
61,864
-78,512
| -56% | -$7.83M | ﹤0.01% | 2702 |
|
|
2023
Q3 | $13.1M | Buy |
140,376
+3,231
| +2% | +$302K | ﹤0.01% | 2020 |
|
|
2023
Q2 | $12.2M | Buy |
137,145
+61,148
| +80% | +$5.32M | ﹤0.01% | 2114 |
|
|
2023
Q1 | $8.15M | Sell |
75,997
-747
| -1% | -$85.5K | ﹤0.01% | 2450 |
|
|
2022
Q4 | $9.37M | Sell |
76,744
-14,375
| -16% | -$1.67M | ﹤0.01% | 2321 |
|
|
2022
Q3 | $9.41M | Sell |
91,119
-33,092
| -27% | -$3.14M | ﹤0.01% | 2195 |
|
|
2022
Q2 | $11.5M | Buy |
124,211
+105,402
| +560% | +$9.93M | ﹤0.01% | 2034 |
|
|
2022
Q1 | $2.21M | Buy |
18,809
+1,530
| +9% | +$177K | ﹤0.01% | 3669 |
|
|
2021
Q4 | $2.32M | Buy |
17,279
+10,317
| +148% | +$1.53M | ﹤0.01% | 3737 |
|
|
2021
Q3 | $1.11M | Buy |
6,962
+1,173
| +20% | +$161K | ﹤0.01% | 4232 |
|
|
2021
Q2 | $762K | Sell |
5,789
-38,699
| -87% | -$5.16M | ﹤0.01% | 4459 |
|
|
2021
Q1 | $5.73M | Buy |
44,488
+36,016
| +425% | +$5.47M | ﹤0.01% | 2851 |
|
|
2020
Q4 | $1.41M | Sell |
8,472
-48,411
| -85% | -$8.01M | ﹤0.01% | 3729 |
|
|
2020
Q3 | $8.66M | Buy |
56,883
+17,611
| +45% | +$2.53M | ﹤0.01% | 2152 |
|
|
2020
Q2 | $5.81M | Buy |
39,272
+3,402
| +9% | +$467K | ﹤0.01% | 2345 |
|
|
2020
Q1 | $4.04M | Buy |
35,870
+17,705
| +97% | +$2.3M | ﹤0.01% | 2448 |
|
|
2019
Q4 | $2.53M | Buy |
18,165
+10,940
| +151% | +$1.22M | ﹤0.01% | 3210 |
|
|
2019
Q3 | $696K | Sell |
7,225
-44,259
| -86% | -$4.94M | ﹤0.01% | 4027 |
|
|
2019
Q2 | $5.58M | Buy |
51,484
+19,160
| +59% | +$2.29M | ﹤0.01% | 2545 |
|
|
2019
Q1 | $3.8M | Buy |
+32,324
| New | +$2.83M | ﹤0.01% | 2818 |
|
|
2018
Q4 | – | Sell |
-852
| Closed | -$60K | – | 5676 |
|
|
2018
Q3 | $60K | Buy |
+852
| New | +$58.6K | ﹤0.01% | 5133 |
|
|
2018
Q2 | – | Sell |
-3,899
| Closed | -$256K | – | 5537 |
|
|
2018
Q1 | $255K | Buy |
+3,899
| New | +$219K | ﹤0.01% | 4285 |
|
|
2017
Q4 | – | Sell |
-201,781
| Closed | -$7.16M | – | 5420 |
|
|
2017
Q3 | $7.16M | Buy |
+201,781
| New | +$5.79M | ﹤0.01% | 2269 |
|
Other funds holding ASND
RCM
ACA
JT
JP Morgan Chase's ASND Position: Q2 2026 in Review
JP Morgan Chase reduced its Ascendis Pharma A/S (ASND) stake by 32% in Q2 2026, selling an estimated $40.1M and leaving 367,781 shares worth $97M. The position accounts for 0.01% of the portfolio, ranked #1091.
JP Morgan Chase first reported a position in ASND in Q3 2017 and has held it in 33 quarters since. The position peaked at $118M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- JP Morgan Chase held 367,781 shares of Ascendis Pharma A/S worth $97M as of Q2 2026.
- JP Morgan Chase sold 171,653 Ascendis Pharma A/S shares in Q2 2026, an estimated $40.1M.
- Ascendis Pharma A/S made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1091 holding.
- JP Morgan Chase first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 33 quarters since.
- JP Morgan Chase's Ascendis Pharma A/S position peaked at $118M in Q1 2026.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.